Posiphen

DRUG2 trials

Sponsors

Annovis Bio Inc.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseParkinson Disease

Phase 1

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

CompletedNCT02925650

Annovis Bio Inc.Alzheimer's Disease

Start: 2017-03-02End: 2021-12-31Updated: 2023-05-09

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

CompletedNCT04524351

Annovis Bio Inc.Alzheimer Disease, Parkinson Disease

Start: 2020-08-14End: 2022-01-31Updated: 2023-02-28

Related Papers

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

Alzheimer s Research & Therapy2024-07-0511 citations

Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients.

2023-01-0133 citations